Nuvation Bio Inc.
Nuvation Bio Inc. (NYSE: NUVB) is a global oncology company that develops and commercializes cancer therapies, focusing on small molecules and drug-drug conjugates. Its commercial product, IBTROZI (taletrectinib), is an oral ROS1 inhibitor approved in the United States for adults with locally advanced or metastatic… From the company’s description.
In fiscal 2025, Nuvation Bio Inc. reported revenue of $62.90M, up 699.0% from fiscal 2024, and a net loss of $204.63M. Its operating margin was −338.7%, and operations used $173.43M in cash. Over the twelve months to Jun 30, 2026, revenue was $169.90M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Nuvation Bio Inc. does
In the company’s own words
Nuvation Bio Inc. (NYSE: NUVB) is a global oncology company that develops and commercializes cancer therapies, focusing on small molecules and drug-drug conjugates. Its commercial product, IBTROZI (taletrectinib), is an oral ROS1 inhibitor approved in the United States for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. The company launched IBTROZI in the United States in June 2025 and partners with Innovent in China and Nippon Kayaku in Japan, where the drug is marketed as DOVBLERON and IBTROZI, respectively. In January 2026, it granted Eisai rights to develop and commercialize taletrectinib in Europe and other territories. Nuvation Bio’s clinical-stage pipeline includes safusidenib, an IDH1 inhibitor being studied in a Phase 3 trial for IDH1-mutant astrocytoma, as well as candidates from its drug-drug conjugate platform. The company had 71 commercial field team members and seven medical affairs field team members supporting its U.S. business in 2025.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 1811063
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Nuvation Bio Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Nuvation Bio Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Nuvation Bio Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Nuvation Bio Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Nuvation Bio Inc.’s debt, $0.13M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.75%, maturing 2032 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Nuvation Bio Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Nuvation Bio Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Nuvation Bio Inc.'s last four quarterly filings that the numbers alone won't show?”